<DOC>
	<DOCNO>NCT00053144</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness combine irinotecan cytarabine treat patient refractory recurrent acute myeloid leukemia chronic myelogenous leukemia .</brief_summary>
	<brief_title>Irinotecan Cytarabine Treating Patients With Refractory Recurrent Acute Myeloid Leukemia Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine activity irinotecan cytarabine patient refractory recurrent acute myeloid leukemia chronic myelogenous leukemia myeloid blast transformation . - Determine pharmacokinetics regimen patient . - Determine maximum tolerate dose irinotecan regimen patient . - Correlate clinical activity drug cellular endpoint associate DNA synthesis inhibition , DNA repair , induction apoptosis , drug resistance patient . OUTLINE : This dose-escalation study irinotecan . Patients receive irinotecan IV 90 minute cytarabine IV 60 minute day 1-6 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . An additional 9 patient refractory/relapsed acute myeloid leukemia 9 patient chronic myelogenous leukemia myeloid blast transformation treat MTD . Patients follow survival . PROJECTED ACCRUAL : A total 3-36 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia ( M0M7 ) De novo secondary disease Previously treat refractory prior therapy ( include highdose cytarabine anthracycline ) Antecedent hematologic disorder allow OR Histologically confirm Philadelphia chromosomepositive chronic myelogenous leukemia myeloid blast transformation Treated untreated Blast transformation define least 20 % blast marrow and/or blood Myeloid lineage define immunophenotyping PATIENT CHARACTERISTICS : Age 15 Performance status 03 Life expectancy At least 4 week Hematopoietic See Disease Characteristics Hepatic Bilirubin less 2 time upper limit normal ( ULN ) SGOT le 2 time ULN Renal Creatinine less 1.5 time ULN Other Not pregnant nursing Negative pregnancy test No concurrent serious medical psychiatric illness would preclude study consent PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Prior chemotherapy antecedent malignancy medical condition allow Endocrine therapy Not specify Radiotherapy Prior radiotherapy antecedent malignancy medical condition allow Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
</DOC>